Bioengineering virus-like particles as vaccines

Biotechnology and Bioengineering

Volumn 111, Issue 3, 2014, Pages 425-440

  Lua, Linda H L ^a   Connors, Natalie K ^a   Sainsbury, Frank ^a   Chuan, Yap P ^a   Wibowo, Nani ^a   Middelberg, Anton P J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Capsomere; Computational; Epitope; Modular; Synthetic biology; Vaccine

Indexed keywords

CAPSOMERE; COMPUTATIONAL; COMPUTATIONAL DESIGN; COST-EFFECTIVE PRODUCTION; INTERDISCIPLINARY ACTIVITIES; MODULAR; SYNTHETIC BIOLOGY; VIRUS-LIKE PARTICLES;

ENZYME ACTIVITY; EPITOPES; PROTEINS; PURIFICATION; VACCINES;

VIRUSES;

ANTIGEN; CANCER VACCINE; CAPSID PROTEIN; VIRUS LIKE PARTICLE VACCINE;

BIOENGINEERING; BIOPROCESS; CELL FREE SYSTEM; COST; DRUG DESIGN; DRUG FORMULATION; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; LIPID MEMBRANE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PURIFICATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VACCINE PRODUCTION; VIRUS CHARACTERIZATION; VIRUS LIKE AGENT; WART VIRUS;

HARNESS;

CAPSOMERE; COMPUTATIONAL; EPITOPE; MODULAR; SYNTHETIC BIOLOGY; VACCINE;

BIOENGINEERING; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84892785219     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25159     Document Type: Review

References (191)

1. Abbing A, Blaschke UK, Grein S, Kretschmar M, Stark CM, Thies MJ, Walter J, Weigand M, Woith DC, Hess J, Resier CO. 2004. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 279(26):27410-27421.
2. Adrian M, Dubochet J, Lepault J, McDowall AW. 1984. Cryo-electron microscopy of viruses. Nature 308(5954):32-36.
3. Aguilar JC, Rodriguez EG. 2007. Vaccine adjuvants revisited. Vaccine 25(19):3752-3762.
4. Ahlers JD, Belyakov IM. 2009. Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines. Trends Mol Med 15(6):263-274.
5. Akinobu K, Fumio A, Makoto T, Hiroaki Y, Akihiro K, Hiroshi H. 1996. Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. Biochimica et Biophysica Acta 1290(1):37-45.
6. Anggraeni MR, Connors NK, Wu Y, Chuan YP, Lua LHL, Middelberg APJ. 2013. Sensitivity of immune response quality to influenza helix 190 antigen structure displayed on a modular virus-like particle. Vaccine 31(40):4428-4435.
7. Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, Padilla DP, Phillips B, Carter MB, Willman CL, et al. 2011. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. Acs Nano 5(7):5729-5745.
8. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. 1993. The influence of antigen organization on B-cell responsiveness. Science 262(5138):1448-1451.
9. Baek J-O, Seo J-W, Kim I-H, Kim CH. 2011. Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography. Protein Expres Purif 75(2):211-217.
10. Barouch DH, Harrison SC. 1994. Interactions among the major and minor coat proteins of polyomavirus. J Virol 68(6):3982-3989.
11. Beterams G, Bottcher B, Nassal M. 2000. Packaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsids. FEBS Lett 481(2):169-176.
12. Bin Park S. 2012. Hepatitis E vaccine debuts. Nature 491(7422):21-22.
13. Birnbaum F, Nassal M. 1990. Hepatitis B virus nucleocapsid assembly: Primary structure requirements in the core protein. J Virol 64(7):3319-3330.
14. Bisht H, Chugh DA, Raje M, Swaminathan S, Khanna N. 2002. Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen. J Biotechnol 99(2):97-110.
15. Bräutigam S, Snezhkov E, Bishop DHL. 1993. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 192(2):512-524.
16. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, et al. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25(19):3871-3878.
17. Brown LE, Kelso A. 2009. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 87(4):300-308.
18. Bundy BC, Swartz JR. 2011. Efficient disulfide bond formation in virus-like particles. J Biotechnol 154(4):230-239.
19. Bundy BC, Franciszkowicz MJ, Swartz JR. 2008. Escherichia coli-based cell-free synthesis of virus-like particles. Biotechnol Bioeng 100(1):28-37.
20. Buonaguro L, Tagliamonte M, Visciano ML, Tornesello ML, Buonaguro FM. 2013. Developments in virus-like particle-based vaccines for HIV. Expert Rev Vaccines 12(2):119-127.
21. Caldeira J, Peabody D. 2007. Stability and assembly in vitro of bacteriophage PP7 virus-like particles. J Nanobiotechnol 5(1):10.
22. Carrillo-Tripp M, Shepherd CM, Borelli IA, Venkataraman S, Lander G, Natarajan P, Johnson JE, Brooks CL, Reddy VS. 2009. VIPERdb(2): An enhanced and web API enabled relational database for structural virology. Nucleic Acids Res 37:D436-D442.
23. Castro-Acosta RM, Revilla AL, Ramirez OT, Palomares LA. 2010. Separation and quantification of double- and triple-layered rotavirus-like particles by CZE. Electrophoresis 31(8):1376-1381.
24. Chackerian B. 2007. Virus-like particles-flexible platforms for vaccine development. Expert Rev Vaccines 6(3):381-390.
25. Chen XS, Casini G, Harrison SC, Garcea RL. 2001. Papillomavirus capsid protein expression in Escherichia coli: Purification and assembly of HPV11 and HPV16 L1. J Mol Biol 307(1):173-182.
26. Chen BJ, Leser GP, Morita E, Lamb RA. 2007. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 81(13):7111-7123.
27. Chuan YP, Fan YY, Lua L, Middelberg APJ. 2008. Quantitative analysis of virus-like particle size and distribution by field-flow Fractionation. Biotechnol Bioeng 99(6):1425-1433.
28. 2+ -triggered switch in the thermodynamic attraction between structural protein capsomeres. J R Soc Interface 7(44):409-421.
29. Chuan YP, Rivera-Hernandez T, Wibowo N, Connors NK, Wu Y, Hughes FK, Lua LHL, Middelberg APJ. 2013. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine. Biotechnol Bioeng 110(9):2343-2351.
30. Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, Hu YC. 2006. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 12(6):921-927.
31. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. 2008. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal, challenge. Vaccine 26(15):1855-1862.
32. Citkowicz A, Petry H, Harkins RN, Ast O, Cashion L, Goldmann C, Bringmann P, Plummer K, Larsen BR. 2008. Characterization of virus-like particle assembly for DNA delivery using asymmetrical flow field-flow fractionation and light scattering. Anal Biochem 376(2):163-172.
33. Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD, Highfield PE, Rowlands DJ, Brown F. 1987. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330(6146):381-384.
34. Conner ME, Zarley CD, Hu B, Parsons S, Drabinski D, Greiner S, Smith R, Jiang B, Corsaro B, Barniak V, et al. 1996. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis 174(Suppl 1):S88-S92.
35. Cook JC. 2003. Process for purifying human papillomavirus virus-like particles.
36. Cook JC, Joyce JG, George HA, Schultz LD, Hurni WM, Jansen KU, Hepler RW, Ip C, Lowe RS, Keller PM, et al. 1999. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expres Purif 17(3):477-484.
37. Crawford SE, Labbé M, Cohen J, Burroughs MH, Zhou YJ, Estes MK. 1994. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol 68(9):5945-5952.
38. D'Aoust MA, Lavoie PO, Couture MM, Trepanier S, Guay JM, Dargis M, Mongrand S, Landry N, Ward BJ, Vezina LP. 2008. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 6(9):930-940.
39. Dell K, Koesters R, Linnebacher M, Klein C, Gissmann L. 2006. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine 24(13):2238-2247.
40. Deschuyteneer M, Elouahabi A, Plainchamp D, Plisnier M, Soete D, Corazza Y, Lockman L, Giannini S, Deschamps M. 2010. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccines 6(5):407-419.
41. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, et al. 2009. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183(10):6186-6197.
42. Ding Y, Chuan YP, He LZ, Middelberg APJ. 2010. Modeling the competition between aggregation and self-assembly during virus-like particle processing. Biotechnol Bioeng 107(3):550-560.
43. Eriksson M, Andreasson K, Weidmann J, Lundberg K, Tegerstedt K, Dalianis T, Ramqvist T. 2011. Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor. PLoS ONE 6(8):e23828.
44. Fernandes F, Teixeira AP, Carinhas N, Carrondo MJT, Alves PM. 2013. Insect cells as a production platform of complex virus-like particles. Expert Rev Vaccines 12(2):225-236.
45. Fernandez E, Toledo JR, Mendez L, Gonzalez N, Parra F, Martin-Alonso JM, Limonta M, Sanchez K, Cabrales A, Estrada MP, et al. 2013. Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine. PLos ONE 8(2):e56417.
46. Fiedler JD, Brown SD, Lau JL, Finn MG. 2010. RNA-directed packaging of enzymes within virus-like particles. Angew Chem Int Ed Engl 49(50):9648-9651.
47. Fligge C, Giroglou T, Streeck RE, Sapp M. 2001. Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology 283(2):353-357.
48. Freivalds J, Dislers A, Ose V, Skrastina D, Cielens I, Pumpens P, Sasnauskas K, Kazaks A. 2006. Assembly of bacteriophage Qβ virus-like particles in yeast Saccharomyces cerevisiae and Pichia pastoris. J Biotechnol 123(3):297-303.
49. Freivalds J, Dislers A, Ose V, Pumpens P, Tars K, Kazaks A. 2011. Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris. Protein Expres Purif 75(2):218-224.
50. French TJ, Roy P. 1990. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J Virol 64(4):1530-1536.
51. Galarza JM, Latham T, Cupo A. 2005. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18(1):244-251.
52. Galeazzi R. 2009. Molecular dynamics as a tool in rational drug design: Current status and some major applications. Curr Comput Aided Drug Des 5(4):225-240.
53. Giles BM, Ross TM. 2011. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29(16):3043-3054.
54. Giles BM, Bissel SJ, DeAlmeida DR, Wiley CA, Ross TM. 2012a. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol 19(2):128-139.
55. Giles BM, Crevar CJ, Carter DM, Bissel SJ, Schultz-Cherry S, Wiley CA, Ross TM. 2012b. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 205(10):1562-1570.
56. Glasgow JE, Capehart SL, Francis MB, Tullman-Ercek D. 2012. Osmolyte-mediated encapsulation of proteins inside MS2 viral capsids. ACS Nano 6(10):8658-8664.
57. GlaxoSmithKline. 2013a. Cervarix product monograph.
58. GlaxoSmithKline. 2013b. Energix-B product monograph.
59. Gleiter S, Lilie H. 2001. Coupling of antibodies via protein Z on modified polyoma virus-like particles. Protein Sci 10(2):434-444.
60. Good MF, Engwerda C. 2011. Defying malaria: Arming T cells to halt malaria. Nat Med 17(1):49-51.
61. Grimes JM, Burroughs JN, Gouet P, Diprose JM, Malby R, Zientara S, Mertens PPC, Stuart DI. 1998. The atomic structure of the bluetongue virus core. Nature 395(6701):470-478.
62. Guillen G, Aguilar JC, Duenas S, Hermida L, Guzman MG, Penton E, Iglesias E, Junco J, Torrens I, Lobaina Y, et al. 2010. Virus-like particles as vaccine antigens and adjuvants: Application to chronic disease, cancer immunotherapy and infectious disease preventive strategies. Global Vaccine Res Forum 2(2):128-133.
63. He YQ, Rappuoli R, De Groot AS, Chen RT. 2010. Emerging vaccine informatics. J Biomed Biotechnol 2010. (2010):1-26.
64. He YQ, Cao ZW, De Groot AS, Brusic V, Schonbach C, Petrovsky N. 2013. Computational vaccinology and the ICoVax 2012 workshop. BMC Bioinformatics 14. (suppl4):l1.
65. Hewat EA, Booth TF, Roy P. 1994. Structure of correctly self-assembled bluetongue virus-like particles. J Struct Biol 112(3):183-191.
66. Hillaire ML, Osterhaus AD, Rimmelzwaan GF. 2011. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011:939860.
67. Hu L, Trefethen JM, Zeng Y, Yee L, Ohtake S, Lechuga-Ballesteros D, Warfield KL, Aman MJ, Shulenin S, Unfer R, et al. 2011. Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles. J Pharma Sci 100(12):5156-5173.
68. Ibañez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, Pollard C, Schepens B, Grooten J, Fiers W, et al. 2013. M2e-displaying virus-like particles with associated RNA promote T Helper 1 Type adaptive immunity against influenza A. PLoS ONE 8(3):e59081.
69. Inoue T, Kawano MA, Takahashi RU, Tsukamoto H, Enomoto T, Imai T, Kataoka K, Handa H. 2008. Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3. J Biotechnol 134(1-2):181-192.
70. Jagu S, Kwak K, Garcea RL, Roden RBS. 2010. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 28(28):4478-4486.
71. Jennings GT, Bachmann MF. 2008. Coming of age of virus-like particle vaccines. Biol Chem 389(5):521-536.
72. Jorgensen WL. 2004. The many roles of computation in drug discovery. Science 303(5665):1813-1818.
73. Joshi H, Cheluvaraja S, Somogyi E, Brown DR, Ortoleva P. 2011a. A molecular dynamics study of loop fluctuation in human papillomavirus type 16 virus-like particles: A possible indicator of immunogenicity. Vaccine 29(51):9423-9430.
74. Joshi H, Singharoy A, Sereda YV, Cheluvaraja SC, Ortoleva PJ. 2011b. Multiscale simulation of microbe structure and dynamics. Prog Biophy Mol Biol 107(1):200-217.
75. Kaczmarczyk SJ, Sitaraman K, Young HA, Hughes SH, Chatterjee DK. 2011. Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A 108(41):16998-17003.
76. Kalnciema I, Skrastina D, Ose V, Pumpens P, Zeltins A. 2012. Potato virus Y-like particles as a new carrier for the presentation of foreign protein stretches. Mol Biotechnol 52(2):129-139.
77. Kang SM, Kim MC, Compans RW. 2012. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 11(8):995-1007.
78. Kato S, Kobayashi K, Inoue K, Kuramochi M, Okada T, Yaginuma H, Morimoto K, Shimada T, Takada M, Kobayashi K. 2011. A lentiviral strategy for highly efficient retrograde gene transfer by pseudotyping with fusion envelope glycoprotein. Hum Gene Ther 22(2):197-206.
79. Kawano M, Matsui M, Handa H. 2013. SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier. Expert Rev Vaccines 12(2):199-210.
80. Keller SA, Bauer M, Manolova V, Muntwiler S, Saudan P, Bachmann MF. 2010. Cutting edge: Limited specialization of dendritic cell subsets for MHC Class II-associated presentation of viral particles. J Immunol 184(1):26-29.
81. Keswani RK, Pozdol IM, Pack DW. 2013. Design of hybrid lipid/retroviral-like particle gene delivery vectors. Mol Pharm 10(5):1725-1735.
82. Kibenge FSB, Qian B, Nagy E, Cleghorn JR, Wadowska D. 1999. Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. Can J Vet Res 63(1):49-55.
83. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. 1992. Papillomavirus L1 Major Capsid Protein Self-Assembles into Virus-Like Particles That Are Highly Immunogenic. Proc Natl Acad Sci U S A 89(24):12180-12184.
84. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67(12):6929-6936.
85. Kissmann J, Ausar SF, Foubert TR, Brock J, Switzer MH, Detzi EJ, Vedvick TS, Middaugh CR. 2008. Physical stabilization of norwalk virus-like particles. J Pharma Sci 97(10):4208-4218.
86. Kissmann J, Joshi SB, Haynes JR, Dokken L, Richardson C, Middaugh CR. 2011. H1N1 influenza virus-like particles: Physical degradation pathways and identification of stabilizers. J Pharma Sci 100(2):634-645.
87. Kuroda D, Shirai H, Jacobson MP, Nakamura H. 2012. Computer-aided antibody design. Protein Eng Des Sel 25(10):507-521.
88. Kushnir N, Streatfield SJ, Yusibov V. 2012. Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine 31(1):58-83.
89. Kuznetsov YG, McPherson A. 2011. Atomic force microscopy in imaging of viruses and virus-infected cells. Microbiol Mol Biol Rev 75(2):268-285.
90. Lang R, Winter G, Vogt L, Zurcher A, Dorigo B, Schimmele B. 2009. Rational design of a stable, freeze-dried virus-like particle-based vaccine formulation. Drug Dev Ind Pharm 35(1):83-97.
91. Lang R, Vogt L, Zurcher A, Winter G. 2010. Virus-like particle characterization using AF4 channel technology. Am Lab 42(5):13.
92. Lapelosa M, Gallicchio E, Arnold GF, Arnold E, Levy RM. 2009. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes. J Mol Biol 385(2):675-691.
93. Lapelosa M, Arnold GF, Gallicchio E, Arnold E, Levy RM. 2010. Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes. J Mol Biol 397(3):752-766.
94. Latham T, Galarza JM. 2001. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 75(13):6154-6165.
95. Lavelle L, Gingery M, Phillips M, Gelbart WM, Knobler CM, Cadena-Nava RD, Vega-Acosta JR, Pinedo-Torres LA, Ruiz-Garcia J. 2009. Phase diagram of self-assembled viral capsid protein polymorphs. J Phys Chem B 113(12):3813-3819.
96. Li T-C, Takeda N, Kato K, Nilsson J, Xing L, Haag L, Cheng RH, Miyamura T. 2003. Characterization of self-assembled virus-like particles of human polyomavirus BK generated by recombinant baculoviruses. Virology 311(1):115-124.
97. Li H-Y, Han J-F, Qin C-F, Chen R. 2013. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31(32):3281-3287.
98. Liew MWO, Rajendran A, Middelberg APJ. 2010. Microbial production of virus-like particle vaccine protein at gram-per-litre levels. J Biotechnol 150(2):224-231.
99. Liew MWO, Chuan YP, Middelberg APJ. 2012. High-yield and scalable cell-free assembly of virus-like particles by dilution. Biochem Eng J 67(0):88-96.
100. Lin TW, Porta C, Lomonossoff G, Johnson JE. 1996. Structure-based design of peptide presentation on a viral surface: The crystal structure of a plant/animal virus chimera at 2.8 angstrom resolution. Fold Des 1(3):179-187.
101. Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, Lin AN, Chiang BL. 2012. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 30(7):1305-1312.
102. Lipin DI, Chuan YP, Lua LHL, Middelberg APJ. 2008a. Encapsulation of DNA and non-viral protein changes the structure of murine polyomavirus virus-like particles. Arch Virol 153(11):2027-2039.
103. Lipin DI, Lua LHL, Middelberg APJ. 2008b. Quaternary size distribution of soluble aggregates of glutathione-S-transferase-purified viral protein as determined by asymmetrical flow field flow fractionation and dynamic light scattering. J Chromatogr A 1190(1-2):204-214.
104. Lipin DI, Raj A, Lua LHL, Middelberg APJ. 2009. Affinity purification of viral protein having heterogeneous quaternary structure: Modeling the impact of soluble aggregates on chromatographic performance. J Chromatogr A 1216(30):5696-5708.
105. Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH. 2000. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 273(2):374-382.
106. Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G. 2011. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 29(38):6606-6613.
107. Lynch A, Meyers A, Williamson A-L, Rybicki E. 2012. Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media. Virol J 9(1):210.
108. Mach H, Volkin DB, Troutman RD, Wang B, Luo Z, Jansen KU, Shi L. 2006. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci 95(10):2195-2206.
109. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. 2011. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 100(10):4171-4197.
110. Manayani DJ, Thomas D, Dryden KA, Reddy V, Siladi ME, Marlett JM, Rainey GJA, Pique ME, Scobie HM, Yeager M, et al. 2007. A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS Pathog 3(10):1422-1431.
111. McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA. 1998. Quantitative Disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol 72(1):32-41.
112. McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG. 2011. Assembly and Immunological Properties of Newcastle Disease Virus-Like Particles Containing the Respiratory Syncytial Virus F and G Proteins. J Virol 85(1):366-377.
113. McGuigan LC, Stallard V, Roos JM, Payne LG. 1993. Recombinant-expressed virus-like particle pseudotypes as an approach to vaccine development. Vaccine 11(6):675-678.
114. Mellado MCM, Mena JA, Lopes A, Ramirez OT, Carrondo MJT, Palomares LA, Alves PM. 2009. Impact of physicochemical parameters on in vitro assembly and disassembly kinetics of recombinant triple-layered rotavirus-like particles. Biotechnol Bioeng 104(4):674-686.
115. Merck 2013a. Gardasil product monograph.
116. Merck 2013b. Recombivax HB product monograph.
117. Metz SW, Gardner J, Geertsema C, Le TT, Goh L, Vlak JM, Suhrbier A, Pijlman GP. 2013. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 7(3):e2124.
118. Miao YL, Ortoleva PJ. 2006. Viral structural transitions: An all-atom multiscale theory. J Chem Phy 125(214901):1-11.
119. Miao YL, Ortoleva PJ. 2010. Viral structural transition mechanisms revealed by multiscale molecular dynamics/order parameter eXtrapolation simulation. Biopolymers 93(1):61-73.
120. Middelberg APJ, Rivera-Hernandez T, Wibowo N, Lua LHL, Fan YY, Magor G, Chang C, Chuan YP, Good MF, Batzloff MR. 2011. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 29(41):7154-7162.
121. Milhiet P-E, Dosset P, Godefroy C, Le Grimellec C, Guigner J-M, Larquet E, Ronzon F, Manin C. 2011. Nanoscale topography of hepatitis B antigen particles by atomic force microscopy. Biochimie 93(2):254-259.
122. Minten IJ, Hendriks LJ, Nolte RJ, Cornelissen JJ. 2009. Controlled encapsulation of multiple proteins in virus capsids. J Am Chem Soc 131(49):17771-17773.
123. Mohr J, Chuan YP, Wu Y, Lua LHL, Middelberg APJ. 2013. Virus-like particle formulation optimization by miniaturized high-throughput screening. Methods 60(3):248-256.
124. Mulder AM, Carragher B, Towne V, Meng Y, Wang Y, Dieter L, Potter CS, Washabaugh MW, Sitrin RD, Zhao Q. 2012. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: A case study with hepatitis B vaccine. PLoS ONE 7(4):e33235.
125. Murata Y, Lightfoote PM, Rose RC, Walsh EE. 2009. Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virol J 6:10.
126. Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG. 2010. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 84(2):1110-1123.
127. Nema S, Washkuhn RJ, Brendel RJ. 1997. Excipients and their use in injectable products. PDA J Pharm Sci Technol 51(4):166-171.
128. Noad R, Roy P. 2003. Virus-like particles as immunogens. Trends Microbiol 11(9):438-444.
129. Ohlschlager P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Muller M, Pawlita M, Schafer K, Sehr P, et al. 2003. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 77(8):4635-4645.
130. Ohtake N, Niikura K, Suzuki T, Nagakawa K, Mikuni S, Matsuo Y, Kinjo M, Sawa H, Ijiro K. 2010. Low pH-triggered model drug molecule release from virus-like particles. Chembiochem 11(7):959-962.
131. O'Neil A, Reichhardt C, Johnson B, Prevelige PE, Douglas T. 2011. Genetically programmed in vivo packaging of protein cargo and its controlled release from bacteriophage P22. Angew Chem Int Ed Engl 50(32):7425-7428.
132. Palomares LA, Ramirez OT. 2009. Challenges for the production of virus-like particles in insect cells: The case of rotavirus-like particles. Biochem Eng J 45(3):158-167.
133. Pankavich SD, Ortoleva PJ. 2012. Nanosystem self-assembly pathways discovered via all-atom multiscale analysis. J Phys Chem B 116(29):8355-8362.
134. Pattenden LK, Middelberg APJ, Niebert M, Lipin DI. 2005. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol 23(10):523-529.
135. Peacey M, Wilson S, Baird MA, Ward VK. 2007. Versatile RHDV virus-like particles: Incorporation of antigens by genetic modification and chemical conjugation. Biotechnol Bioeng 98(5):968-977.
136. Pease LF, Lipin DI, Tsai D-H, Zachariah MR, Lua LHL, Tarlov MJ, Middelberg APJ. 2009. Quantitative characterization of virus-like particles by asymmetrical flow field flow fractionation, electrospray differential mobility analysis, and transmission electron microscopy. Biotechnol Bioeng 102(3):845-855.
137. Pejawar-Gaddy S, Rajawat Y, Hilioti Z, Xue J, Gaddy D, Finn O, Viscidi R, Bossis I. 2010. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother 59(11):1685-1696.
138. Petrovsky N, Aguilar JC. 2004. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 82(5):488-496.
139. Phelps JP, Dao P, Jin H, Rasochova L. 2007. Expression and self-assembly of cowpea chlorotic mottle virus-like particles in Pseudomonas fluorescens. J Biotechnol 128(2):290-296.
140. Plummer EM, Manchester M. 2011. Viral nanoparticles and virus-like particles: Platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol 3(2):174-196.
141. Porta C, Kotecha A, Burman A, Jackson T, Ren J, Loureiro S, Jones IM, Fry EE, Stuart DI, Charleston B. 2013. Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. PLoS Pathog 9(3):e1003255.
142. Prasad BVV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. 1999. X-ray crystallographic structure of the Norwalk virus capsid. Science 286(5438):287-290.
143. Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, Tumpey TM. 2011. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 29(35):5911-5918.
144. Pushko P, Pumpens P, Grens E. 2013. Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology 56(3):141-165.
145. Ramqvist T, Andreasson K, Dalianis T. 2007. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther 7(7):997-1007.
146. Rasmussen L, Battles JK, Ennis WH, Nagashima K, Gonda MA. 1990. Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus. Virology 178(2):435-451.
147. Rivera-Hernandez T, Hartas J, Wu Y, Chuan YP, Lua LHL, Good M, Batzloff MR, Middelberg APJ. 2013. Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). Vaccine 31(15):1950-1955.
148. Roberts JA, Kuiper MJ, Thorley BR, Smooker PM, Hung A. 2012. Investigation of a predicted N-terminal amphipathic et-helix using atomistic molecular dynamics simulation of a complete prototype poliovirus virion. J Mol Grap Model 38:165-173.
149. Rodriguez-Limas WA, Tyo KEJ, Nielsen J, Ramirez OT, Palomares LA. 2011. Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. Microb Cell Fact 10(33):1-10.
150. Roldao A, Mellado MCM, Castilho LR, Carrondo MJ, Alves PM. 2010. Virus-like particles in vaccine development. Expert Rev Vaccines 9(10):1149-1176.
151. Roldao A, Mellado MCM, Lima JC, Carrondo MJT, Alves PM, Oliveira R. 2012. On the effect of thermodynamic equilibrium on the assembly efficiency of complex multi-layered virus-like particles (VLP): The case of rotavirus VLP. PLoS Comput Biol 8(2):e1002367.
152. Roose K, De Baets S, Schepens B, Saelens X. 2013. Hepatitis B core-based virus-like particles to present heterologous epitopes. Expert Rev Vaccines 12(2):183-198.
153. Rose RC, White WI, Li ML, Suzich JA, Lane C, Garcea RL. 1998. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 72(7):6151-6154.
154. Sainsbury F, Saunders K, Aljabali AAA, Evans DJ, Lomonossoff GP. 2011. Peptide-controlled access to the interior surface of empty virus nanoparticles. ChemBioChem 12(16):2435-2440.
155. Salunke DM, Caspar DL, Garcea RL. 1986. Self-assembly of purified polyomavirus capsid protein VP1. Cell 46(6):895-904.
156. Saunders K, Sainsbury F, Lomonossoff GP. 2009. Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants. Virology 393(2):329-337.
157. Schadlich L, Senger T, Gerlach B, Mucke N, Klein C, Bravo IG, Muller M, Gissmann L. 2009. Analysis of modified human papillomavirus type 16 L1 capsomeres: The ability to assemble into larger particles correlates with higher immunogenicity. J Virol 83(15):7690-7705.
158. Schmidt U, Rudolph R, Bohm G. 2000. Mechanism of assembly of recombinant murine polyomavirus-like particles. J Virol 74(4):1658-1662.
159. Schneemann A, Speir JA, Tan GS, Khayat R, Ekiert DC, Matsuoka Y, Wilsona IA. 2012. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol 86(21):11686-11697.
160. Scotti N, Rybicki EP. 2013. Virus-like particles produced in plants as potential vaccines. Expert Rev Vaccines 12(2):211-224.
161. Seow Y, Wood MJ. 2009. Biological gene delivery vehicles: Beyond viral vectors. Mol Therapy 17(5):767-777.
162. Shi L, Sanyal G, Ni A, Luo Z, Doshna S, Wang B, Graham TL, Wang N, Volkin DB. 2005. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci 94(7):1538-1551.
163. Shivachandra SB, Rao M, Janosi L, Sathaliyawala T, Matyas GR, Alving CR, Leppla SH, Rao VB. 2006. In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: A strategy for efficient display of large full-length proteins. Virology 345(1):190-198.
164. Shreif Z, Adhangale P, Cheluvaraja S, Perera R, Kuhn R, Ortoleva P. 2008. Enveloped viruses understood via multiscale simulation: Computer-aided vaccine design. Sci Model Simul 15(1-3):363-380.
165. Stanley M, Lowy DR, Frazer I. 2006. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 24 Supplement 3 (0):S106-S113.
166. Steinmetz NF, Evans DJ, Lomonossoff GP. 2007. Chemical introduction of reactive thiols into a viral nanoscaffold: A method that avoids virus aggregation. ChemBioChem 8(10):1131-1136.
167. Taylor KM, Lin TW, Porta C, Mosser AG, Giesing HA, Lomonossoff GP, Johnson JE. 2000. Influence of three-dimensional structure on the immunogenicity of a peptide expressed on the surface of a plant virus. J Mol Recogn 13(2):71-82.
168. Tegerstedt K, Franzen A, Ramqvist T, Dalianis T. 2007. Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor. Cancer Immunol Immunother 56(9):1335-1344.
169. Thones N, Herreiner A, Schadlich L, Piuko K, Muller M. 2008. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J Virol 82(11):5472-5485.
170. Valenzuela P, Medina A, Rutter WJ. 1982. Synthesis and assembly of hepatitis-b virus surface-antigen particles in yeast. Nature 298(5872):347-350.
171. Velasquez LS, Shira S, Berta AN, Kilbourne J, Medi BM, Tizard I, Ni Y, Arntzen CJ, Herbst-Kralovetz MM. 2011. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 29(32):5221-5231.
172. Velez RA, de Matos APA, Parreira R, Piedade J, Matos B, Correia C, Esteves A. 2012. Expression of Chikungunya virus-like particles. Microsc Microanal 18:59-60.
173. Vieira HLA, Estevao C, Roldao A, Peixoto CC, Sousa MFQ, Cruz PE, Carrondo MJT, Alves PM. 2005. Triple layered rotavirus VLP production: Kinetics of vector replication, mRNA stability and recombinant protein production. J Biotechnol 120(1):72-82.
174. Voelkel C, Galla M, Maetzig T, Warlich E, Kuehle J, Zychlinski D, Bode J, Cantz T, Schambach A, Baum C. 2010. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci U S A 107(17):7805-7810.
175. Walpita P, Barr J, Sherman M, Basler CF, Wang LF. 2011. Vaccine potential of Nipah virus-like particles. PLoS ONE 6(4):e18437.
176. Warfield KL, Aman MJ. 2011. Advances in virus-like particle vaccines for filoviruses. J Infect Dis 204:S1053-S1059.
177. Weldon RA, Jr., Erdie CR, Oliver MG, Wills JW. 1990. Incorporation of chimeric gag protein into retroviral particles. J Virol 64(9):4169-4179.
178. Whitacre DC, Lee BO, Milich DR. 2009. Use of hepadnavirus core proteins as vaccine platforms. Expert Rev Vaccines 8(11):1565-1573.
179. White LJ, Hardy ME, Estes MK. 1997. Biochemical characterization of a smaller form of recombinant Norwalk virus capsids assembled in insect cells. J Virol 71(10):8066-8072.
180. Wibowo N, Chuan YP, Lua LHL, Middelberg APJ. 2013. Modular engineering of a microbially-produced viral capsomere vaccine for influenza. Chem Eng Sci 103:12-20.
181. Wu M, Brown WL, Stockley PG. 1995. Cell-specific delivery of bacteriophage-encapsidated ricin A chain. Bioconjug Chem 6(5):587-595.
182. Wu WH, Gersch E, Kwak K, Jagu S, Karanam B, Huh WK, Garcea RL, Roden RBS. 2011. Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS ONE 6(11):e27141.
183. Wynne SA, Crowther RA, Leslie AGW. 1999. The crystal structure of the human hepatitis B virus capsid. Mol Cell 3(6):771-780.
184. Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, Garcea RL, Schlegel R. 2001. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 75(17):7848-7853.
185. Zeltins A. 2013. Construction and characterization of virus-like particles: A review. Mol Biotechnol 53(1):92-107.
186. Zhang LF, Zhou J, Chen S, Cai LL, Bao QY, Zheng FY, Lu JQ, Padmanabha J, Hengst K, Malcolm K, et al. 2000. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18(11-12):1051-1058.
187. Zhang L, Tang RH, Bai S, Connors NK, Lua LHL, Chuan YP, Middelberg APJ, Sun Y. 2013. Molecular energetics in the capsomere of virus-like particle revealed by molecular dynamics simulations. J Phys Chem B 117(18):5411-5421.
188. Zhao X, Fox JM, Olson NH, Baker TS, Young MJ. 1995. In vitro assembly of cowpea chlorotic mottle virus from coat protein expressed in Escherichia coli and in vitro-transcribed viral cDNA. Virology 207(2):486-494.
189. Zhao Q, Allen MJ, Wang Y, Wang B, Wang N, Shi L, Sitrin RD. 2012a. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine 8(7):1182-1189.
190. Zhao Q, Modis Y, High K, Towne V, Meng Y, Wang Y, Alexandroff J, Brown M, Carragher B, Potter CS, et al. 2012b. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol J 9:52.
191. Zhu F-C, Zhang J, Zhang X-F, Zhou C, Wang Z-Z, Huang S-J, Wang H, Yang C-L, Jiang H-M, Cai J-P, et al. 2010. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: A large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376(9744):895-902.